Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe

British Journal of Clinical Pharmacology

Volumn 84, Issue 6, 2018, Pages 1324-1334

  Hider Mlynarz, Karima ^a   Cavalié, Philippe ^a   Maison, Patrick ^a  

^a Department of Epidemiology of Health Products   (France)

Author keywords

analgesics; consumption; Europe; France; non opioids; opioids

Indexed keywords

ANALGESIC AGENT; BUPRENORPHINE; CODEINE; DEXTROPROPOXYPHENE; FENTANYL; HYDROMORPHONE; MORPHINE; NALBUPHINE; OXYCODONE; PARACETAMOL; PETHIDINE; TRAMADOL; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ARTICLE; COMPARATIVE STUDY; DRUG MARKETING; EUROPE; FRANCE; PHARMACEUTICAL CARE; PRESCRIPTION; PRIORITY JOURNAL; TREND STUDY; CLINICAL PRACTICE; COMMERCIAL PHENOMENA; DRUG THERAPY; FACTUAL DATABASE; HUMAN; TIME FACTOR; TRENDS;

ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; COMMERCE; DATABASES, FACTUAL; DRUG THERAPY; FRANCE; HUMANS; PRACTICE PATTERNS, PHYSICIANS'; TIME FACTORS;

EID: 85044716913     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13564     Document Type: Article

References (55)

1. Turunen JHO, Mäntyselkä PT, Kumpusalo EA, Ahonen RS. Frequent analgesic use at population level: prevalence and patterns of use. Pain 2005; 115: 374–381.
2. World Health Organization. Traitement de la douleur cancéreuse. Geneva: World Health Organization, 1997.
3. Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res 2012; 18: 228–245.
4. Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Bucher-Bartelson B, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015; 372: 241–248.
5. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010; 363: 1981–1985.
6. Gedeborg R, Svennblad B, Holm L, Sjogren H, Bardage C, Personne M, et al. Increased availability of paracetamol in Sweden and incidence of paracetamol poisoning: using laboratory data to increase validity of a population-based registry study. Pharmacoepidemiol Drug Saf 2017; 26: 518–527.
7. Titchen T, Cranswick N, Beggs S. Adverse drug reactions to nonsteroidal anti-inflammatory drugs, COX-2 inhibitors and paracetamol in a paediatric hospital. Br J Clin Pharmacol 2005; 59: 718–723.
8. Labianca R, Sarzi-Puttini P, Zuccaro SM, Cherubino P, Vellucci R, Fornasari D. Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. Clin Drug Investig 2012; 32: 53–63.
9. Hudec R, Bozekova L, Tisonova J. Consumption of three most widely used analgesics in six European countries. J Clin Pharm Ther 2012; 37: 78–80.
10. Kristensen DM, Mazaud-Guittot S, Gaudriault P, Lesne L, Serrano T, Main KM, et al. Analgesic use – prevalence, biomonitoring and endocrine and reproductive effects. Nat Rev Endocrinol 2016; 12: 381–393.
11. Bandieri E, Chiarolanza A, Luppi M, Magrini N, Marata AM, Ripamonti C. Prescription of opioids in Italy: everything, but the morphine. Ann Oncol 2009; 20: 961–962.
12. Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 2006; 125: 172–179.
13. French National Agency for Medicines and Health Products Safety. Analyse des ventes de médicaments en 2013. Saint-Denis, 2014. Available at http://ansm.sante.fr/var/ansm_site/storage/original/application/3df7b99f8f4c9ee634a6a9b094624341.pdf (last accessed 14 March 2018)
14. Gulmez SE, Larrey D, Pageaux GP, Bernuau J, Bissoli F, Horsmans Y, et al. Liver transplant associated with paracetamol overdose: results from the seven-country SALT study. Br J Clin Pharmacol 2015; 80: 599–606.
15. Moore N, Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, et al. Choice of the denominator in case population studies: event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France. Pharmacoepidemiol Drug Saf 2013; 22: 160–167.
16. Hebbes C, Lambert D. Non-opioid analgesics. Anaesth Intensive Care Med 2011; 12: 69–72.
17. Van Boeckel T, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014; 14: 742–750.
18. WHO Collaboring Centre for Drugs Statistics Methodology. Complete ATC index 2016. Available at http://www.whocc.no/atcddd/ (last accessed 14 March 2018)
19. Eurostat. Available at http://ec.europa.eu/eurostat/web/population-demography-migration-projections/population-data/main-tables (last accessed 14 March 2018)
20. Daveluy A, Lassale R, Lacueille C, Grelaud A, Batisse A, Dousset V, et al. Prevalence of analgesic use in France, 2006–2014. Fundam Clin Pharmacol 2017; 31: 72.
21. Palmaro A, Lapeyre-Mestre M. Trends in opioid analgesics use in Europe: a ten-year perspective. Clin Ther 2015; 37: e4.
22. Zin CS, Chen LC, Knaggs RD. Changes in trends and pattern of strong opioid prescribing in primary care. Eur J Pain 2014; 18: 1343–1351.
23. Hamunen K, Paakkari P, Kalso E. Trends in opioid consumption in the Nordic countries 2002–2006. Eur J Pain 2009; 13: 954–962.
24. Ruscitto A, Smith BH, Guthrie B. Changes in opioid and other analgesic use 1995–2010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. Eur J Pain 2015; 19: 59–66.
25. European Medicines Agency. Dextropropoxyphene. Available at http%3A%2F%2Fwww.ema.europa.eu%2Fema%2Findex.jsp%3Fcurl%3Dpages%2Fmedicines%2Fhuman%2Freferrals%2Fdextropropoxyphene%2Fhuman_referral_000162.jsp%26amp%3Bmid%3DWC0b01ac05805c516f (last accessed 14 March 2018)
26. Hawton K, Bergen H, Simkin S, Wells C, Kapur N, Gunnell D. Six-year follow-up of impact of coproxamol withdrawal in England and Wales on prescribing and deaths: time-series study. PLoS Med 2012; 9: e1001213.
27. French National Agency for Medicines and Health Products Safety. Mise au point – Prise en charge des douleurs de l'adulte modérée à intenses. 2011. Available at http://www.ansm.sante.fr/var/ansm_site/storage/original/application/a6497f74fc2f18e8db0022973f9327e1.pdf (last accessed 14 March 2018)
28. Gaubert S, Vie M, Damase-Michel C, Pathak A, Montastruc JL. Dextropropoxyphene withdrawal from a French university hospital: impact on analgesic drug consumption. Fundam Clin Pharmacol 2009; 23: 247–252.
29. Aubrun F, Chrétien E, Letrilliart L, Ginoux M, Belhassen M, Lanteri-Minet M, et al. What are the therapeutic alternatives to dextropropoxyphene in France ? A prescribers' survey. Anaesth Crit Care Pain Med 2017; 36: 15–19.
30. Duong M, Gulmez SE, Salvo F, Abouelfath A, Lassalle R, Droz C, et al. Usage patterns of paracetamol in France. Br J Clin Pharmacol 2016; 82: 498–503.
31. Varrassi G, Muller-Schwefe G, Pergolizzi J, Oronska A, Morlion B, Mavrocordatos P, et al. Pharmacological treatment of chronic pain – the need for CHANGE. Curr Med Res Opin 2010; 26: 1231–1245.
32. World Health Organization, ed. Cancer Pain Relief: With a Guide to Opioid Availability, 2nd edn edn. Geneva: World Health Organization, 1996.
33. McQuay HJ, Moore RA. Dose-response in direct comparisons of different doses of aspirin, ibuprofen and paracetamol (acetaminophen) in analgesic studies. Br J Clin Pharmacol 2007; 63: 271–278.
34. Tong HY, Medrano N, Borobia AM, Martinez AM, Martin J, Ruiz JA, et al. Hepatotoxicity induced by acute and chronic paracetamol overdose in adults. Where do we stand? Regul Toxicol Pharmacol 2015; 72: 370–378.
35. Berterame S, Erthal J, Thomas J, Fellner S, Vosse B, Clare P, et al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet 2016; 387: 1644–1656.
36. Caraceni AT, Brunelli C, Rocco P, Minghetti P. Trends in opioid analgesics sales to community pharmacies and hospitals in Italy (2000–2010). Minerva Anestesiol 2013; 79: 906–914.
37. Chenaf C, Kabore J, Delorme J, Roche L, Escalier A, Delage N, et al. Trends in opioid analgesic use, doctor shopping and mortality in France from 2004 to 2014. Fundam Clin Pharmacol 2016; 30: 30–31.
38. Garcia del Pozo J, Carvajal A, Viloria JM, Velasco A, Garcia del Pozo V. Trends in the consumption of opioid analgesics in Spain. Higher increases as fentanyl replaces morphine. Eur J Clin Pharmacol 2008; 64: 411–415.
39. Schubert I, Ihle P, Sabatowski R. Increase in opiate prescription in Germany between 2000 and 2010: a study based on insurance data. Dtsch Arztebl Int 2013; 110: 45–51.
40. Dhalla IA, Persaud N, Juurlink DN. Facing up to the prescription opioid crisis. BMJ 2011; 343: d5142.
41. Elliott TE, Elliott BA. Physician attitudes and beliefs about use of morphine for cancer pain. J Pain Symptom Manage 1992; 7: 141–148.
42. Toye F, Seers K, Tierney S, Barker KL. A qualitative evidence synthesis to explore healthcare professionals' experience of prescribing opioids to adults with chronic non-malignant pain. BMC Fam Pract 2017; 18: 94.
43. Helmerhorst GT, Teunis T, Janssen SJ, Ring D. An epidemic of the use, misuse and overdose of opioids and deaths due to overdose, in the United States and Canada: is Europe next? Bone Joint J 2017; 99–B: 856–864.
44. Moisset X, Martinez V. Opioid use for the management of chronic non-cancer pain: French guidelines. Rev Neurol (Paris) 2016; 172: 337–338.
45. Ekholm O, Kurita GP, Højsted J, Juel K, Sjøgren P. Chronic pain, opioid prescriptions, and mortality in Denmark: a population-based cohort study. Pain 2014; 155: 2486–2490.
46. Centers for Disease Control, Prevention Public Health Service US Department of Health and Human Services. Guideline for prescribing opioids for chronic pain. J Pain Palliat Care Pharmacother 2016; 30: 138–140.
47. Volkow ND, McLellan AT. Opioid abuse in chronic pain – misconceptions and mitigation strategies. N Engl J Med 2016; 374: 1253–1263.
48. Bedson J, Chen Y, Hayward RA, Ashworth J, Walters K, Dunn KM, et al. Trends in long-term opioid prescribing in primary care patients with musculoskeletal conditions: an observational database study. Pain 2016; 157: 1525–1531.
49. Birke H, Kurita GP, Sjogren P, Hojsted J, Simonsen MK, Juel K, et al. Chronic non-cancer pain and the epidemic prescription of opioids in the Danish population: trends from 2000 to 2013. Acta Anaesthesiol Scand 2016; 60: 623–633.
50. Mounteney J, Giraudon I, Denissov G, Griffiths P. Fentanyls: are we missing the signs? Highly potent and on the rise in Europe. Int J Drug Policy 2015; 26: 626–631.
51. van Amsterdam J, van den Brink W. The misuse of prescription opioids: a threat for Europe? Curr Drug Abuse Rev 2015; 8: 3–14.
52. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287–333.
53. Jacob L, Kostev K. Prevalence of pain medication prescriptions in France, Germany, and the UK – a cross-sectional study including 4, 270, 142 patients. Postgrad Med 2018; 130: 3236.
54. Find NL, Terlizzi R, Munksgaard SB, Bendtsen L, Tassorelli C, Nappi G, et al. Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study. J Headache Pain 2015; 17: 20.
55. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015; 156: 569–576.